Artelo Biosciences (ARTL) vs GeoVax Labs (GOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.3 million vs $985,459), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | GOVX |
|---|---|---|
| Share price | $1.39 | $1.81 |
| Market cap | $1.30M | $985.46K |
| 1-day change | -4.14% | -5.24% |
| EPS (TTM) | $-20.56 | $-15.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.49M |
| Revenue growth (YoY) | — | -37.06% |
| Net income (latest FY) | $-12.88M | $-21.46M |
| Operating margin | — | -869.34% |
| Net margin | — | -862.34% |
| 52-week high | $179.19 | $270.60 |
| 52-week low | $1.30 | $1.51 |
| Distance from 52-week high | -99.22% | -99.33% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +452.49% |
| Average volume | 476.69K | 213.41K |
| Shares outstanding | 937.18K | 544.45K |
| Employees | 7 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
ARTL vs GOVX FAQ
Which is bigger, Artelo Biosciences or GeoVax Labs?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.30M compared with $985.46K for GeoVax Labs (GOVX).
Are Artelo Biosciences and GeoVax Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.